Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

3

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA

3

DNA (cytosine-5)-methyltransferase 1

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

2006

3

Unknown

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Myelodysplastic syndromes

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

3

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Institute of Organic Chemistry, Czechoslovak Academy of Sciences

3

Merrell Dow Pharmaceuticals, Inc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

NCI_THESAURUS

5

ChEMBL

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIMETABOLITES

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Pyrimidine analogues

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

DECITABINE

776B62CQ27

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 2006

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA (cytosine-5)-methyltransferase 1

Conditions:

Myelodysplastic syndromes

Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon admin...

istration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1).

TEZACITABINE ANHYDROUS

7607Y95N9S

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Tezacitabine is a cytidine derivative patented by Merrell Dow Pharmaceuticals, Inc. as an antineoplastic and antiviral agent. Tezacitabine acts as irreversible ribonucleotide reductase inhibitor and DNA chain terminator. Tezacitabine shows as potent ...

activity in a broad spectrum of tumor cell lines and in vivo tumor models, including human colon, prostate, and breast tumor xenografts, In clinical trials combination of Tezacitabine and 5-Fluorouracil exerts favor influences in patients with advanced solid tumors particularly in patients with esophageal and other gastrointestinal carcinomas.

GUADECITABINE SODIUM

0RB89YH367

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 2006

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA (cytosine-5)-methyltransferase 1

Conditions:

Myelodysplastic syndromes

Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon admin...

istration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1).

GUADECITABINE

2KT4YN1DP7

Export Data
Search for Structure

Status:

US Approved Rx (2013)

First approved in 2006

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

DNA (cytosine-5)-methyltransferase 1

Conditions:

Myelodysplastic syndromes

Decitabine was first synthesized by Pliml and Sorm in the Institute of Organic Chemistry, Czechoslovak Academy of Sciences in 1964. Later, the drug was approved by FDA for the treatment of myelodysplastic syndromes in patients with cancer. Upon admin...

istration the decitabine is metabolized to the active phosphorylated metabolite which is incorporated into DNA and thus inhibits DNA methyltransferase (decitabine deplete DNMT1).

TEZACITABINE HYDROCHLORIDE

Y19296N8M6

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Tezacitabine is a cytidine derivative patented by Merrell Dow Pharmaceuticals, Inc. as an antineoplastic and antiviral agent. Tezacitabine acts as irreversible ribonucleotide reductase inhibitor and DNA chain terminator. Tezacitabine shows as potent ...

activity in a broad spectrum of tumor cell lines and in vivo tumor models, including human colon, prostate, and breast tumor xenografts, In clinical trials combination of Tezacitabine and 5-Fluorouracil exerts favor influences in patients with advanced solid tumors particularly in patients with esophageal and other gastrointestinal carcinomas.

TEZACITABINE

UCC4EQS7WL

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Tezacitabine is a cytidine derivative patented by Merrell Dow Pharmaceuticals, Inc. as an antineoplastic and antiviral agent. Tezacitabine acts as irreversible ribonucleotide reductase inhibitor and DNA chain terminator. Tezacitabine shows as potent ...

activity in a broad spectrum of tumor cell lines and in vivo tumor models, including human colon, prostate, and breast tumor xenografts, In clinical trials combination of Tezacitabine and 5-Fluorouracil exerts favor influences in patients with advanced solid tumors particularly in patients with esophageal and other gastrointestinal carcinomas.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1